|
1
|
Roy R, Yang J and Moses MA: Matrix
metalloproteinases as novel biomarkers and potential therapeutic
targets in human cancer. J Clin Oncol. 931:5287–5297.
2000.PubMed/NCBI
|
|
2
|
Seo DW, Li H, Guedez L, Wingfield PT, Diaz
T, Salloum R, Wei BY and Stetler-Stevenson WG: TIMP-2 mediated
inhibition of angiogenesis: an MMP-independent mechanism. Cell.
114:171–180. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coussens LM, Fingleton B and Matrisian LM:
Matrix metalloproteinase inhibitors and cancer trials and
tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Massi D, Franchi A, Ketabchi S, Paglierani
M, Pimpinelli N and Santucci M: Expression and prognostic
significance of matrix metalloproteinases and their tissue
inhibitors in primary neuroendocrine carcinoma of the skin. Hum
Pathol. 34:80–88. 2003. View Article : Google Scholar
|
|
5
|
Bergers G, Brekken R, McMahon G, et al:
Matrix metalloproteinase-9 triggers the angiogenic switch during
carcinogenesis. Nat Cell Biol. 2:737–744. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baker AH, Edwards DR and Murphy G:
Metalloproteinase inhibitors: biological actions and therapeutic
opportunities. J Cell Sci. 115:3719–3727. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rydlova M, Holubec L Jr and Ludvikova M,
Kalfert D, Franekova J, Povysil C and Ludvikova M: Biological
activity and clinical implications of the matrix
metalloproteinases. Anticancer Res. 28:1389–1398. 2008.PubMed/NCBI
|
|
8
|
Stetler-Stevenson WG and Seo DW: TIMP-2:
an endogenous inhibitor of angiogenesis. Trends Mol Med. 11:97–103.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang H, Wen Y, Mooney S, Li H, Behr B and
Polan ML: Matrix metalloproteinase and tissue inhibitor of matrix
metalloproteinase expression in human preimplantation embryos.
Fertil Steril. 80(Suppl 2): S736–S742. 2003. View Article : Google Scholar
|
|
10
|
Dimo B, Ioannidis I, Karameris A, Vilaras
G, Tzoumakari P, Nonni A, Patsouris E and Lazaris AC: Comparative
study of the Immunohistochemical expression of tissue inhibitors of
metalloproteinases 1 and 2 between clearly invasive carcinomas and
‘in situ’ trophoblast invasion. Med Oncol. 29:2270–2275.
2012.PubMed/NCBI
|
|
11
|
Imren S, Kohn DB, Shimada H, Blavier L and
DeClerk YA: Overexpression of tissue inhibitor of
metalloproteinases-2 retroviral-mediated gene transfer in vivo
inhibits tumor growth and invasion. Cancer Res. 56:2891–2895.
1996.PubMed/NCBI
|
|
12
|
Bourboulia D, Jensen-Taubman S, Rittler
MR, Han HY, Chatterjee T, Wei B and Stetler-Stevenson WG:
Endogenous angionesesis inhibitor blocks tumor growth via direct
and indirect effects on tumor microenvironment. Am J Path.
179:2589–2600. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
DeClerck YA, Perez N, Shimada H, Boone TC,
Langley KE and Taylor SM: Inhibition of invasion and metastasis in
cells transfected with an inhibitor of mettaloproteinases. Cancer
Res. 52:701–708. 1992.PubMed/NCBI
|
|
14
|
Ceolin L, Siqueira DR, Romitti M, Ferreira
CV and Maia AL: Molecular basis of medullary thyroid carcinoma: the
role of RET polymorphisms. Int J Mol Sci. 13:221–239. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Puñales MK, da Rocha AP, Meotti C, Gross
JL and Maia AL: Clinical and oncological features of children and
young adults with multiple endocrine neoplasia type 2A. Thyroid.
18:1261–1268. 2008.PubMed/NCBI
|
|
16
|
Kloos RT, Eng C, Evans DB, Francis GL,
Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M
and Wells SA Jr: Medullary thyroid cancer: management guidelines of
the American Thyroid Association. Thyroid. 19:565–612. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mulligan LM, Kwok JB, Healey CS, Elsdon
MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, et al: Germ-line
mutations of the RET proto-oncogene in multiple endocrine neoplasia
type 2A. Nature. 363:458–460. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hundahl SA, Fleming ID, Fremgen AM and
Menck HR: A National Cancer Data Base report on 53,856 cases of
thyroid carcinoma treated in the U.S., 1985–1995. Cancer.
83:2638–2648. 1998.PubMed/NCBI
|
|
19
|
Mitchell JC and Parangi S: Angiogenesis in
benign and malignant thyroid disease. Thyroid. 15:494–510. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maeta H, Ohgi S and Terada T: Protein
expression of matrix metalloproteinases 2 and 9 and tissue
inhibitors of metalloproteinase 1 and 2 in papillary thyroid
carcinomas. Virchows Arch. 438:121–128. 2001. View Article : Google Scholar
|
|
21
|
Siqueira DR, Romitti M, da Rocha AP,
Ceolin L, Meotti C, Estivalet A, Puñales MK and Maia AL: The RET
polymorphic allele S836S is associated with early metastatic
disease in patients with hereditary or sporadic medullary thyroid
carcinoma. Endocr Relat Cancer. 17:953–963. 2010. View Article : Google Scholar
|
|
22
|
O’Sullivan B and Shah J: New TNM staging
criteria for head and neck tumors. Semin Surg Oncol. 21:30–42.
2003.
|
|
23
|
Nelson AR, Fingleton B, Rothenberg ML and
Matrisian LM: Matrix metalloproteinases: Biologic activity and
clinical implications. J Clin Oncol. 18:1135–1149. 2000.PubMed/NCBI
|
|
24
|
Kumamoto H, Yamauchi K, Yoshida M and Ooya
K: Immunohistochemical detection of matrix metalloproteinases
(MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in
ameloblastomas. J Oral Pathol Med. 32:114–120. 2003. View Article : Google Scholar
|
|
25
|
Lee SJ, Tsang PS, Daz TM, Wei BY and
Stetler-Stevenson WG: TIMP-2 modulates VEGFR-2 phosphorylation and
enhances phosphodiesterase activity in endothelial cells. Lab
Invest. 90:374–382. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cho Mar K, Eimoto T, Tateyama H, Arai Y,
Fujiyoshi Y and Hamaguchi M: Expression of matrix
metalloproteinases in benign and malignant follicular thyroid
lesions. Histopathology. 48:286–294. 2006.PubMed/NCBI
|
|
27
|
Korem S, Kraiem Z, Shiloni E, Yehezkel O,
Sadeh O and Resnick MB: Increased expression of matrix
metalloproteinase-2: a diagnostic marker but not prognostic marker
of papillary thyroid carcinoma. Isr Med Assoc J. 4:247–251.
2002.
|
|
28
|
Albini A, Melchiori A, Santi L, Liotta LA,
Brown PD and Stetler-Stevenson WG: Tumor cell invasion inhibited by
TIMP-2. J Natl Cancer Inst. 83:775–779. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ring P, Johansson K, Höyhtyä M, Rubin K
and Lindmark G: Expression of tissue inhibitor of
metalloproteinases TIMP-2 in human colorectal cancer - a predictor
of tumour stage. Br J Cancer. 76:805–811. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tomita T: Matrix metalloproteinases and
tissue inhibitors of metalloproteinases in thyroid C-cells and
medullary thyroid carcinomas. Histopathology. 31:150–156. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cavalheiro BG, Junqueira CR and Brandão
LG: Expression of matrix metalloproteinase 2 (MMP-2) and tissue
inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid
carcinoma: prognostic implications. Thyroid. 8:865–871. 2008.
View Article : Google Scholar
|
|
32
|
Capp C, Wajner SM, Siqueira DM, Brasil BA,
Meurer L and Maia AL: Increased expression of vascular endothelial
growth factor and its rreceptors, VEGFR-1 and VEGFR-2 in medullary
thyroid carcinoma. Thyroid. 8:863–871. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bunone G, Vigneri P, Mariani L, Buto S,
Collini P, Pilotti S, Pierotti MA and Bongarzone I: Expression of
angiogenesis stimulators and inhibitors in human thyroid tumors and
correlation with clinical pathological features. Am J Pathol.
155:1967–1976. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
de la Torre NG, Buley I, Wass JA and
Turner HE: Angiogenesis and lymphangiogenesis in thyroid
proliferative lesions: relationship to type and tumour behaviour.
Endocr Relat Cancer. 13:931–944. 2006.PubMed/NCBI
|
|
35
|
Roy H, Bhardwaj S and Ylä-Herttuala S:
Biology of vascular endothelial growth factors. FEBS Lett.
580:2879–2887. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lamoreaux WJ, Fitzgerald ME, Reiner A,
Hasty KA and Charles ST: Vascular endothelial growth factor
increases release of gelatinase A and decreases release of tissue
inhibitor of metalloproteinases by microvascular endothelial cells
in vitro. Microvasc Res. 55:29–42. 1998. View Article : Google Scholar
|
